Drug Trial Radar · NCT04104776
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Sep 18, 2019
Primary completion
Feb 27, 2030
Study completion Feb 27, 2030
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 26, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid tumors and lymphomas.
Conditions
- Advanced Solid Tumor
- Diffuse Large B Cell Lymphoma
- Lymphoma, T-Cell
- Mesothelioma, Malignant
- Prostatic Neoplasms, Castration-Resistant
- Endometrial Cancer
- Ovarian Clear Cell Carcinoma
- Metastatic Castration-resistant Prostate Cancer
Interventions
TulmimetostatDrug
Tulmimetostat dosed once per day orally in 28 day cycles
EnzalutamideDrug
Enzalutamide dosed once per day orally in 28 day cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Tulmimetostat Monotherapy Phase 1: Frequency of Dose-limiting toxicities (DLTs)Time frame: DLTs assessed during Cycle 1 (cycle = 28 days)
- Tulmimetostat Monotherapy Phase 2: Overall response rate (ORR)Time frame: Up to 30 months
- Cohort M8 Part 1: Frequency of Dose-limiting toxicities (DLTs)Time frame: DLTs assessed during Cycle 1 (cycle = 28 days)
- Cohort M8 Part 2: Prostate-Specific Antigen 50 (PSA50) ResponseTime frame: Up to 30 months
Locations
80 sites in 7 countries. Site status is shown where the registry gives one.
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida · Withdrawn
Winship Cancer Institute of Emory University
Atlanta, Georgia · Recruiting
University of Chicago Medical Center
Chicago, Illinois · Recruiting
Loyola University Medical Center
Maywood, Illinois · Withdrawn
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland · Withdrawn
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Completed
University of Michigan Hospitals
Ann Arbor, Michigan · Withdrawn
South Texas Accelerated Research Therapeutics (START) - Midwest Location
Grand Rapids, Michigan · Active not recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Completed
Roswell Park Cancer Institute
Buffalo, New York · Withdrawn
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York · Completed
Memorial Sloan Kettering Cancer Center - NYC
New York, New York · Withdrawn
Weill Medical College of Cornell University
New York, New York · Withdrawn
University of Rochester Medical Center, James P. Wilmot Cancer Center
Rochester, New York · Withdrawn
Montefiore Medical Center, Montefiore Medical Center Laboratories
The Bronx, New York · Withdrawn
University of Cincinnati Medical Center
Cincinnati, Ohio · Withdrawn
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
South Texas Accelerated Research Therapeutics
San Antonio, Texas · Completed
University of Virginia Health System
Charlottesville, Virginia · Recruiting
Swedish Cancer Institute
Seattle, Washington · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
CHU Bordeaux Hopital Saint Andre
Bordeaux, France · Withdrawn
CLCC Institut Bergonie
Bordeaux, France · Recruiting
Centre Oscar Lambret
Lille, France · Recruiting
Centre Leon Berard
Lyon, France · Recruiting
CHU Nantes Hopital Hotel Dieu
Nantes, France · Recruiting
CHU Nantes Hopital Nord Laennec
Saint-Herblain, France · Recruiting
Hopital Hautepierre
Strasbourg, France · Recruiting
Gustave Roussy
Villejuif, France · Recruiting
Irccs University Hospital of Bologna
Bologna, Italy · Completed
National Cancer Institute, IRCCS
Milan, Italy · Recruiting
National Cancer Institute, IRCCS
Milan, Italy · Withdrawn
European Institute of Oncology (IEO), IRCCS
Milan, Italy · Completed
European Institute of Oncology (IEO), IRCCS
Milan, Italy · Recruiting
Humanitas San Pio X
Milan, Italy · Recruiting
University Polyclinic Foundation "Agostino Gemelli" - IRCCS
Roma, Italy · Recruiting
Gruppo Humanitas - Humanitas Research Hospital - Cancer Center
Rozzano, Italy · Recruiting
University Teaching Centre, Early Clinical Trials Unit
Gdansk, Poland · Recruiting
Pratia MCM Krakow
Krakow, Poland · Withdrawn
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.